Early Structural, Biochemical, and Metabolic Responses to Anlotinib in Patients With Progressive Radioactive Iodine Refractory Differentiated Thyroid Cancer

Key words

radioactive iodine refractory differentiated thyroid cancer

multikinase inhibitor

anlotinib

18F-FDG-PET/CT

early response

Abbreviations18F-FDG PET/CT

2-deoxy-2-[18F] fluoro-D-glucose positron-emission-tomography/computed-tomography

DTC

differentiated thyroid cancer

ECOG

Eastern Cooperative Oncology Group

EORTC

European Organization for Research and Treatment of Cancer

MKI

multi-kinase inhibitor

PDTC

poorly differentiated thyroid cancer

PERCIST

PET Response Criteria in Solid Tumors

PMD

progressive metabolic disease

PMR

progressive metabolic response

RAIR-DTC

radioactive iodine refractory differentiated thyroid cancer

RECIST 1.1

Response Evaluation Criteria in Solid Tumors version 1.1

SMD

stable metabolic disease

SUVmax

maximum standardized uptake value

TgAb

thyroglobulin antibody

View original article

0 0 0 0 0 0 0

留言 (0)